Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in
treating certain relapsed/refractory hematological cancers. However, CART cell therapy is …

Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and
consolidation chemotherapy alone or in combination with different therapeutic approaches …

In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia
(R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable …

Background Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who
do not respond to or who have progressive disease after salvage therapies have a poor …

Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune
responses. Tumor escape associated with low target antigen expression is emerging as one …

PURPOSE CD19-targeted chimeric antigen receptor (CAR)–modified T cells demonstrate
unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse …

Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …

PURPOSE Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and
there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We …

Over the last decade remarkable progress has been made in enhancing the efficacy of CAR
T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in …

Accumulating research suggests that the tumor immune microenvironment (TIME) plays an
essential role in regulation of tumor growth and metastasis. The cellular and molecular …